Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer

被引：0
|
作者：
Tarantino, Paolo
Lee, Do
Foldi, Julia
Soulos, Pamela R.
Gross, Cary Philip
Grinda, Thomas
Winer, Eric P.
Lin, Nancy U.
Krop, Ian E.
Tolaney, Sara M.
Lustberg, Maryam B.
Sammons, Sarah L.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Yale Sch Med, New Haven, CT USA
[3] UPMC, Pittsburgh, PA USA
[4] Yale Canc Ctr, New Haven, CT USA
[5] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1077
引用
收藏
页数：1
相关论文
共 50 条
  • [31] HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers
    Drago, Joshua Z.
    Pareja, Fresia
    Jhaveri, Komal L.
    Walsh, Elaine M.
    Ku, Geoffrey Yuyat
    Maron, Steven Brad
    Janjigian, Yelena Y.
    Robson, Mark E.
    Reis-Filho, Jorge S.
    Modi, Shanu
    Razavi, Pedram
    Chandarlapaty, Sarat
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Artificial intelligence analysis of advanced breast cancer patients from a phase I trial of trastuzumab deruxtecan (T-DxD): HER2 and histopathology features as predictors of clinical benefit
    Modi, S.
    Glass, B.
    Prakash, A.
    Taylor-Weiner, A.
    Elliott, H.
    Wapinski, I.
    Sugihara, M.
    Saito, K.
    Kerner, J. Kaplan
    Phillips, R.
    Shibutani, T.
    Honda, K.
    Khosla, A.
    Beck, A. H.
    Cogswell, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S355 - S356
  • [33] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Im, Seock-Ah
    Iwata, Hiroji
    Curigliano, Giuseppe
    Kim, Sung-Bae
    Chiu, Joanne Wing-Yan
    Pedrini, Jose Luiz
    Li, Wei
    Yonemori, Kan
    Bianchini, Giampaolo
    Loi, Sherene
    Borges, Giuliano Santos
    Wang, Xian
    Bachelot, Thomas
    Nakatani, Shunsuke
    Ashfaque, Shahid
    Liang, Zhengkang
    Egorov, Anton
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] The Real-World Clinical Outcomes of Heavily Pretreated HER2+and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
    Lazaratos, Anna-Maria
    Dankner, Matthew
    Hamouda, Aalya
    Labidi, Soumaya
    Cohen, Victor
    Panasci, Lawrence
    Friedmann, Jennifer E.
    Patenaude, Francois
    Ferrario, Cristiano
    Basik, Mark
    Rose, April A. N.
    Fallah, Parvaneh
    CURRENT ONCOLOGY, 2025, 32 (01)
  • [35] Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial
    Epaillard, N.
    Lusque, A.
    Pistilli, B.
    Andre, F.
    Bachelot, T.
    Pierga, J-Y.
    Ducoulombier, A.
    Jouannaud, C.
    Viret, F.
    Salabert, L.
    Johnson, A. C.
    Deluche, E.
    Durando, X.
    Petit, T.
    Filleron, T.
    Oukhatar, C. Mahier Ait
    Dieras, V. C.
    Mosele, M. F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S656 - S656
  • [36] Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer
    Sandhya Mehta
    Jipan Xie
    Raluca Ionescu-Ittu
    Xiaoyu Nie
    Winghan J. Kwong
    Oncology and Therapy, 2023, 11 : 481 - 493
  • [37] Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+?Metastatic Breast Cancer
    Mehta, Sandhya
    Xie, Jipan
    Ionescu-Ittu, Raluca
    Nie, Xiaoyu
    Kwong, Winghan J.
    ONCOLOGY AND THERAPY, 2023, 11 (04) : 481 - 493
  • [38] Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience
    Bahceci, Aykut
    Paydas, Semra
    Ak, Naziye
    Ferhatoglu, Ferhat
    Saip, Pinar Mualla
    Seydaoglu, Gulsah
    Bilici, Mehmet
    Simsek, Melih
    Tekin, Salim Basol
    Calikusu, Zuleyha
    Yavuz, Sinan
    Sahin, Ahmet Bilgehan
    Cubukcu, Erdem
    Evrensel, Turkkan
    Degirmencioglu, Serkan
    Demiray, Atike Gokcen
    Yumuk, Perran Fulden
    Alan, Ozkan
    Cikman, Duygu Ilke
    Demirelli, Fuat Hulusi
    Kostek, Osman
    Gokyer, Ali
    Dogan, Mutlu
    Bal, Oznur
    Cakar, Burcu
    Gokmen, Erhan
    Yamac, Deniz
    Korkmaz, Taner
    Aliyev, Altay
    Keskin, Ozge
    Urvay, Semiha
    Buyuksimsek, Mahmut
    Karadeniz, Cemile
    Yildiz, Birol
    Cinkir, Havva Yesil
    Demir, Hacer
    Beypinar, Ismail
    Karacin, Cengiz
    Eser, Kadir
    Baykara, Meltem
    Kilickap, Saadettin
    Okutur, Kerem
    Bulut, Gulcan
    Alkan, Ali
    Arpaci, Erkan
    Pilanci, Kezban Nur
    Demir, Atakan
    Isik, Deniz
    Yildirim, Nilgun
    CANCER INVESTIGATION, 2021, 39 (6-7) : 473 - 481
  • [39] Spotlight on Trastuzumab Deruxtecan (DS-8201, T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
    Azar, Ibrahim
    Alkassis, Samer
    Fukui, Jami
    Alsawah, Fares
    Fedak, Kalub
    Al Hallak, Mohammed Najeeb
    Sukari, Ammar
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 103 - 114
  • [40] FEASIBILITY ASSESSMENT OF AN INDIRECT TREATMENT COMPARISON (ITC) OF SACITUZUMAB GOVITECAN (SG) VS TRASTUZUMAB DERUXTECAN (T-DXD) IN HR+/HER2-METASTATIC BREAST CANCER (MBC)
    Shah, A.
    Thaliffdeen, R.
    Proudman, D.
    Verret, W.
    Sjekloca, N.
    Campone, M.
    VALUE IN HEALTH, 2023, 26 (12) : S545 - S545
12345